Featured Research

from universities, journals, and other organizations

Hopkins Offers Non-Laser Correction Farsightedness

Date:
October 1, 2002
Source:
Johns Hopkins Medical Institutions
Summary:
Surgeons at Johns Hopkins' Wilmer Eye Institute are now offering conductive keratoplasty, or CK, to correct low-level farsightedness in selected patients over age 40. The procedure, approved in April by the U.S. Food and Drug Administration, is the first non-laser treatment for hyperopia, a condition in which people can see objects far away but have trouble focusing on those nearby.

Surgeons at Johns Hopkins' Wilmer Eye Institute are now offering conductive keratoplasty, or CK, to correct low-level farsightedness in selected patients over age 40.

The procedure, approved in April by the U.S. Food and Drug Administration, is the first non-laser treatment for hyperopia, a condition in which people can see objects far away but have trouble focusing on those nearby. It is an outpatient surgery performed under local anesthesia in just a few minutes .

Unlike laser treatments, which use light waves as an energy source, CK uses radiofrequency waves, a form of electromagnetic energy, to re-shape the peripheral cornea. The energy is similar in some respects to the microwaves that power CB radios and cell phones.

CK employs a pen-shaped instrument with a tip as thin as a human hair that releases the radiofrequency energy. The tip is applied in a circular pattern on the outer layer of the front of the eyeball to shrink small areas of tissue. The result is a constrictive band of tissue, similar to a tightened belt, that increases the overall curvature of the cornea.

"Nearly 95 percent of patients with low to moderate ranges of farsightedness achieve normal or near-normal vision after the procedure," says Terrence P. O'Brien, M.D., medical director of the Wilmer Laser Vision Center in Lutherville, Md.

About 60 million Americans have some hyperopia, characterized by a shortened or too flat cornea. When light enters a hyperopic eyeball, it focuses behind the retina instead of directly on the retina, forcing the focusing apparatus of the eye to work to compensate and clarify fuzzy images.

Symptoms include eyestrain, blurred vision or headache, especially when reading or at the end of the day. The condition can be corrected with prescription contact lenses and eye glasses, or surgically treated by steepening the central cornea or flattening the peripheral cornea.

Radiofrequency technology, also used for prostate cancer therapy, back surgery and some cardiovascular procedures, is still in clinical trials for the treatment of nearsightedness and astigmatism.

For more information about CK, call the Wilmer Laser Vision Center at 410-583-2802 or check their Web site at http://www.wilmerlaser.net

Related Web site:

The Johns Hopkins Wilmer Eye Institute:http://www.wilmer.jhu.edu


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Hopkins Offers Non-Laser Correction Farsightedness." ScienceDaily. ScienceDaily, 1 October 2002. <www.sciencedaily.com/releases/2002/09/020927070440.htm>.
Johns Hopkins Medical Institutions. (2002, October 1). Hopkins Offers Non-Laser Correction Farsightedness. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2002/09/020927070440.htm
Johns Hopkins Medical Institutions. "Hopkins Offers Non-Laser Correction Farsightedness." ScienceDaily. www.sciencedaily.com/releases/2002/09/020927070440.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins